In the second in our 3-part Q&A series, IRSF's CEO Melissa Kennedy shares important information about the accessibility and affordability of DAYBUE and future treatments like it, and what you can do NOW to advocate. Some of the questions IRSF's Tim Frank covers include:

- What happens after FDA approval?
- What will DAYBUE cost?
- What do we know now about trofinetide's availability outside the United States?

You can find all videos in this series, plus audio-only versions and transcripts in English and Spanish, on our website at rettsyndrome.org/trofinetidevideos.

Learn more about DAYBUE at daybue.com. Find links to resources and share your reaction to this historic news on our website at rettsyndrome.org/trofinetideapproved. Raise awareness for Rett syndrome by writing to your state officials using our simple advocacy tool at rettsyndrome.org/advocacy.

Make sure to like or follow our channel to be notified when the final video in the series is available.

Disclaimer: All information is intended for informational purposes only and is not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding your specific medical condition.